Afluxin for GERD: safety and performance study
Part of Digestive system clinical trials.
This trial tests a new treatment called Afluxin for people with gastroesophageal reflux disease (GERD), which causes heartburn and regurgitation. It aims to see if Afluxin is safe and works better than a placebo (inactive control) to relieve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have heartburn or regurgitation (sour taste) that started at least 7 days ago and is mild to moderate.
- You have not taken any heartburn medicine (like omeprazole, ranitidine, antacids, or alginates) in the last week.
- You are willing to use birth control (if you could become pregnant) and have a negative pregnancy test before starting.
- You do not have other serious stomach or esophagus conditions (like a large hiatal hernia, Barrett's esophagus, or stomach cancer).
- You have not had stomach or esophagus surgery, and you are not taking NSAIDs or steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a procedure called Endoscopic Cardial Constriction Ligation (ECCL) to help people whose acid reflux doesn't improve with strong medication. It uses a thin, flexible tube with a camera to tighten the valve between the stomach and esophagus.
This registry study follows people with long-term acid reflux (GERD) who get the RefluxStop treatment. It mainly collects real-world safety and performance information to see how well the device helps over time.
This study will track how well the RefluxStop device works and its safety for treating acid reflux in a general hospital setting. It aims to help people with long-term GERD who have not found relief from other treatments.
This trial tests a new way to treat GERD (chronic acid reflux) using a tiny camera and a device that delivers a gentle heat treatment (argon plasma coagulation) to the area where the stomach meets the esophagus. It's compared to a 'sham' procedure (you won't know which you get) to see if it stops acid from backing up better than medicine alone.
This study tests a new topical treatment for people with chronic heartburn and acid regurgitation who don't have erosions (damage) in their esophagus. The treatment is applied directly to the affected area and may help relieve symptoms without taking daily pills.
This trial tests a new medicine called anaprazole for people with moderate to severe reflux esophagitis (chronic heartburn and damage to the food pipe). It compares anaprazole to a standard treatment to see which works better and is safer.
Hear when a new Gastroesophageal Reflux Disease (GERD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.